98%
921
2 minutes
20
Face mask (FM) therapy used for maxillary protraction improves the facial profile in patients with Class III malocclusion. The aim of this study was to compare the sagittal morphological changes of the maxilla through three different therapeutic approaches, respectively using removable appliances (RA), rapid maxillary expansion (RME) and surgically assisted rapid maxillary expansion (SARME), each of them in combination with the FM therapy in growing and non-growing patients. The sample, consisting of 42 orthodontic patients aged 7-21, was divided into four groups, according to their age. The first group of patients, aged 6-9 (RA + FM group), received treatment with RA in combination with FM, the second group of patients, aged 10-13 (RME + FM pubertal group), received treatment with RME in combination with FM, the third group of patients, aged 14-16 (RME + FM postpubertal group), received treatment with RME and FM, and the fourth group of patients, aged 17-21 (SARME + FM group), underwent SARME in combination with FM. To assess the sagittal skeletal changes of the maxilla, the sella-nasion-A point (SNA) and A point-nasion-B point (ANB) angles were measured at the beginning and after the FM therapy. The differences in the evolution of the SNA angle between the groups were statistically significant (p<0.001). Post-hoc analysis showed that patients aged 6-9 had the highest evolution, statistically higher than patients aged 14-16 (p=0.007) or patients aged 17-21 (p<0.001). The evolution of the SNA angle was significantly higher in patients aged 10-13, in comparison to patients aged 17-21 (p<0.001). The efficiency of the FM therapy alone or associated with RME depends on patients' growing period. In non-growing patients, the FM therapy is efficient when associated with SARME.
Download full-text PDF |
Source |
---|
BMC Psychol
September 2025
Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg, 405 30, Sweden.
Patients' sense of safety and well-being may be affected in numerous ways while being cared for in hospitals. Often, feelings of alienation arise, as private spaces like the home are inaccessible. One aspect that impacts patients' safety and well-being is the design of the physical care environment.
View Article and Find Full Text PDFThorax
September 2025
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Introduction: Breathlessness is a common cause of hospital admission globally and is associated with high mortality, particularly in low-income countries. In sub-Saharan Africa, there is a paucity of data on breathlessness, with existing data focused on individual diseases. There is a need for patient-centred approaches to understand interactions between multiple conditions to address population needs and inform health system responses.
View Article and Find Full Text PDFPharmacoepidemiol Drug Saf
September 2025
Sanofi, Cambridge, Massachusetts, USA.
Purpose: Given the increased likelihood for individuals with severe asthma to experience comorbidities, disease complications, emergency room visits, and hospitalizations, the ability to stratify asthma populations on severity is often important. Although pharmacoepidemiologic studies using administrative healthcare databases sometimes categorize asthma severity, there is no consensus on an approach.
Methods: Individuals with asthma (≥ 2 ICD-10-CM diagnosis codes J45) aged ≥ 6 years were identified in Optum's de-identified Clinformatics Data Mart Database between January 2017 and November 2023.
Ren Fail
December 2025
Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
This study aimed to develop a predictive model and construct a graded nomogram to estimate the risk of severe acute kidney injury (AKI) in patients without preexisting kidney dysfunction undergoing liver transplantation (LT). Patients undergoing LT between January 2022 and June 2023 were prospectively screened. Severe AKI was defined as Kidney Disease: Improving Global Outcomes stage 3.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
August 2025
The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only curative option for myelofibrosis (MF) but is often underutilized in patients aged ≥ 65 due to concerns about treatment-related toxicity.
Methods: We conducted a retrospective analysis of chronic-phase MF allo-HCT recipients using the publicly available CIBMTR P-5640 dataset (2008-2019). Key endpoints included overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-vs-host disease (GVHD)-related outcomes.